Acasti Pharma is in the healthcare sector and is in the biotechnology industry. The company CEO is Janelle D’Alvise. Acasti Pharma Inc is engaged in the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil.
Previous Intraday Performance:
The ACST shares had a previous change of -2.80% which opened at 0.91 and closed at 0.88. It moved to an intraday high of 0.91 and a low of 0.86.
SeekingAlpha: Acasti Pharma advancing development of CaPre for high triglycerides
Historical Performance:
Over the last five trading days, ACST shares returned 0.00% and in the past 30 trading days it returned -8.05%. Over three months, it changed -7.38%. In one year it has changed 17.35% and within that year its
52 week high was 1.80 and its 52 week low was 0.43. ACST stock is 103.09% above its 52 week low.
Our calculations result in a 200 day moving average of 0.88 and a 50 day moving average of 0.93. Right now, ACST stock is trading -0.14% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.
SeekingAlpha: Acasti Pharma advancing development of CaPre for high triglycerides
Liquidity:
The company has a market cap of $68.8m with 78.1m shares outstanding and a float of 78.1m shares. Trading volume was 126,993 shares and has experienced an average volume of 225,302 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
Below was the last reported quarterly diluted earnings per share:
| 4th | Qtr 2018 | -0.05 |
|---|---|---|
| 3rd | Qtr 2018 | -0.48 |
| 2nd | Qtr 2018 | -0.18 |
| 1st | Qtr 2018 | -0.26 |
| 4th | Qtr 2017 | -0.31 |
The long-term trend of the EPS is a vital number as it helps understand the future potential of Acasti Pharma.
Indicators Also to Watch:
Based on the latest filings, there is 3.90% of institutional ownership.
The beta was calculated to be 1.07.
SeekingAlpha: Axcelis Technologies, Inc. (ACLS) CEO Mary Puma on Q1 2019 Results – Earnings Call Transcript
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -184.86%, return on assets is -97.40% and price-to-book is 3.12.
Company Score Card:
Results are out of six:
0 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Acasti Pharma, ACST, Biotechnology, Healthcare
